Abstract: Objective To investigate the possibility of beneficial effects of sodium-glucose co-transporter-2(SGTL-2)inhibitors on prognosis after acute myocardial infarction(AMI). Methods Randomized controlled trails meeting the inclusion criteria were selected through computer searches of PubMed, Cochrane Library, Embase, CNKI, Wanfang Database and VIP Journal database from the establishment of the database to August 2024. Outcome indicators included: hospitalization for heart failure; all-cause death; cardiovascular death; MACE events; SGLT-2 inhibitor related adverse effects. Results A total of 6 randomized controlled trails were included in the meta-analysis, with a total of 11 012 patients. The results showed that SGLT-2 inhibitors in addition to standard treatment after AMI reduced the risk of hospitalization for heart failure(RR=0.76, 95%CI=0.62~0.93, P=0.01). However, there was no significant difference in the risk of all-cause death(RR=1.00, 95%CI=0.83~1.21, P=0.97), cardiovascular death(RR=1.01, 95%CI=0.82~1.25, P=0.92), MACE events(RR=1.03, 95%CI=0.87~1.21, P=0.76), and SGLT-2 inhibitor related adverse effects(RR=1.03, 95%CI=0.96~1.10, P=0.38), compared with placebo. Conclusion The addition of SGLT-2 inhibitors to standard treatment after AMI is safe and can reduce the risk of hospitalization for heart failure after AMI, but the risks of all-cause death, cardiovascular death and MACE events are not significantly increased or decreased.

Key words: sodium-glucose co-transporter-2 inhibitor, acute myocardial infarction, randomized controlled trail, Meta-analysis